us fda receives 21% boost in programme level budget for fy2003

PharmacoEconomics & Outcomes News 402 - 8 Mar 2003 ■ The US FDA received a programme level budget of $US1.64 billion when the US President signed the FY2003 Omnibus Appropriation Bill in February this year, representing a 21% increase compared with the FY2002 omnibus. The legislation will provide the FDA’s generic drugs programme with an additional $US5.3 million, while the improvement of patient protection against medical errors involving FDA- regulated drugs, medical devices and biologicals will also receive $US5 million. Food and Drug Administration. Statement of Dr. Mark McClellan, Commissioner of Food and Drugs on Approval of the Omnibus Appropriation Bill. Media Release : 19 Feb 2003. Available from: URL: http:// www.fda.gov 809018829 1 PharmacoEconomics & Outcomes News 8 Mar 2003 No. 402 1173-5503/10/0402-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Post on 23-Dec-2016

217 views

Category:

Documents

2 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: US FDA receives 21% boost in programme level budget for FY2003

PharmacoEconomics & Outcomes News 402 - 8 Mar 2003

■ The US FDA received a programme level budget of$US1.64 billion when the US President signed theFY2003 Omnibus Appropriation Bill in February thisyear, representing a 21% increase compared with theFY2002 omnibus. The legislation will provide theFDA’s generic drugs programme with an additional$US5.3 million, while the improvement of patientprotection against medical errors involving FDA-regulated drugs, medical devices and biologicals willalso receive $US5 million.Food and Drug Administration. Statement of Dr. Mark McClellan,Commissioner of Food and Drugs on Approval of the Omnibus AppropriationBill. Media Release : 19 Feb 2003. Available from: URL: http://www.fda.gov 809018829

FY2003 Presentation of Q1 Results · 2018-04-27 · 7 Q1 FY2003 Overview of Consolidated Profit & Loss ・The Internet Advertising Media Business saw an expansion in Opt-in Mail sales

ROCHE TO ACQUIRE FLATIRONexperience, along with your CV or resume, to Hillman Director Robert L. Ferris, MD, PhD (care of [email protected] ). ... 24 Lilly receives additional FDA

Systematic Approach to Pharmacovigilance beyond the Limits ......Once a drug receives FDA approval, it undergoes post-marketing surveillance which includes a review of post-approval

Interim Financial Report for FY2003 · 1 Interim Financial Report for FY2003 (April 2002-March2003) November 2002 Osaka Gas Co.,Ltd

Chemicals in the Environment, FY2003

Annual Report FY2003

FY2003 FY2007 FY2011 C F D

Food & Beverage Industry Brochure - daemar.com · applications including: FDA Silcone, FDA EPDM, FDA NBR, FDA Neoprene, FDA FKM (Viton), FDA PTFE, FDA PTFE Encapsulated, FFKM (Kalrez)

Consolidated Financial Results for FY2003 First Half · FY2002 24,134 19.80 18.37 Notes: ① Equity in net income of unconsolidated subsidiaries and affiliates FY2003 1st. Half 4,138

FY2003 Approved Budget (242 Pages)

Fiscal 2004 Consolidated Interim Earnings Report · · 2017-11-211. Equity-method loss: 1st Half of FY2004 – 610 ; 1st Half of FY2003 – None; FY2003; None 2. ... Period-end

R&D Plan in FY2003 Vertex Detector Subgroup Y. Sugimoto 11 Apr. 2003